Aldeyra Therapeutics Files DEF 14A on Executive Compensation
Ticker: ALDX · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1341235
Sentiment: neutral
Topics: executive-compensation, sec-filing, governance
Related Tickers: ALDX
TL;DR
Aldeyra's 2025 DEF 14A shows exec comp details for 2024, including equity awards for NEOs and Non-NEOs.
AI Summary
Aldeyra Therapeutics, Inc. filed its DEF 14A on April 25, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted to its Named Executive Officers (NEOs) and Non-NEOs. For the fiscal year 2024, the company reported equity awards for its NEOs and Non-NEOs, with specific details on year-end values of outstanding and unvested awards.
Why It Matters
This filing provides transparency into how Aldeyra Therapeutics compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures about executive compensation and corporate governance, but can sometimes reveal information impacting stock valuation or investor confidence.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation details.)
- 20250425 — Filing Date (Date the DEF 14A was submitted to the SEC.)
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Filer
- 0001341235 (company) — Central Index Key
- 20250425 (date) — Filing Date
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to disclose information regarding Aldeyra Therapeutics, Inc.'s executive compensation, director compensation, and corporate governance practices for the fiscal year ending December 31, 2024.
Who are the Named Executive Officers (NEOs) of Aldeyra Therapeutics for the fiscal year 2024?
The filing indicates that there are Named Executive Officers (NEOs) for the fiscal year 2024, and details their equity awards, but their specific names are not listed in the provided excerpt.
What type of compensation details are provided for Non-NEO members?
The filing provides details on equity awards granted to Non-NEO members for the fiscal year 2024, including year-end values of outstanding and unvested awards.
What is the fiscal year end for Aldeyra Therapeutics?
Aldeyra Therapeutics' fiscal year ends on December 31st.
When was this DEF 14A filing submitted?
This DEF 14A filing was submitted on April 25, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Aldeyra Therapeutics, Inc. (ALDX).